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Each year schistosomiasis afﬂicts up to 600 million people in 74 tropical and sub-tropical
countries, predominantly in the developing world. Yet we depend on a single drug,
praziquantel, for its treatment and control. There is no vaccine available but one is
urgently needed especially since praziquantel-resistant parasites are likely to emerge
at some time in the future. The disease is caused by several worm species of the
genus Schistosoma. These express several classes of papain-like cysteine peptidases,
cathepsins B and L, in various tissues but particularly in their gastrodermis where they
employ them as digestive enzymes. We have shown that sub-cutaneous injection of
recombinant and functionally active Schistosoma mansoni cathepsin B1 (SmCB1), or a
cathepsin L from a related parasite Fasciola hepatica (FhCL1), elicits highly signiﬁcant
protection (up to 73%) against an experimental challenge worm infection in murine models
of schistosomiasis. The immune modulating properties of this subcutaneous injection
can boost protection levels (up to 83%) when combined with other S. mansoni vaccine
candidates, glyceraldehyde 3-phosphate dehydrogenase (SG3PDH) and peroxiredoxin
(PRX-MAP). Here, we discuss these data in the context of the parasite’s biology and
development, and provide putative mechanism by which the native-like cysteine peptidase
induce protective immune responses.
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Schistosomiasis is caused by several helminth (worm) species of
the genus Schistosoma, including Schistosoma mansoni, S. haema-
tobium, and S. japonicum and is endemic in 74 tropical and
sub-tropical countries, most prevalently in Africa, the Middle
East, South America, and South-East Asia. Diagnostic tools for
the detection of infection lack sensitivity and/or speciﬁcity lead-
ing the World Health Organization (WHO) to no longer provide
estimates on populations infected or at risk but rather replacing
this by describing the situation as “population requiring pre-
ventive chemotherapy.” A recent WHO report (World Health
Organization [WHO], 2012) revealed that the total number of
people needing preventive chemotherapy globally for 2010 was
over 237 million, of these > 108 million were school-age chil-
dren, and of which only 13% received treatment. Praziquantel
is the only readily available effective drug for the treatment of
the three main parasites causing human schistosomiasis, and
has the advantages of low cost and self-limiting side effects.
However, complete cure is seldom achieved such that for mod-
erate (100–400 eggs per gram feces, epg) and heavy ( >400
epg) infections the cure rate may not exceed 60%. Conse-
quently, a substantial proportion of treated individuals can
remain infected (probably unaware) and, therefore, are at risk
of the serious sequelae of chronic schistosomiasis (Barsoum et al.,
2013).
We cannot remain dependent on a single drug for the treat-
ment and control of schistosomiasis as it is likely that in some
time praziquantel-resistant parasites will emerge and, therefore,
a vaccine for schistosomiasis is urgently needed. Schistosomes
live intravascularly throughout their time spent in the mam-
malian host; the mature adult worms can reside in the mesenteric
or pelvic veins for decades and are highly refractory to blood-
borne immune defense elements. However, there is evidence
that human populations can develop immune-mediated resis-
tance to re-infection and, at least in animals, there is evidence
that vaccine-related protective immune responses can be induced
against the parasites. Schistosome larvae (cercariae) attenuated
with gamma, X-ray, or ultraviolet radiation are capable of infect-
ing their host through the skin but they do not survive to migrate
beyond the lung stage; most are eliminated over a protracted
time period of up to three weeks or more after infection (Harrop
andWilson, 1993). Laboratory animals immunized with radiation
attenuated (RA) cercariae of S. mansoni and S. haematobium are
protected against challenge infection with normal cercariae, with
reductions in worm burdens compared to non-vaccinated ani-
mals varying from 30–90% depending on the host, schistosome
species and strain, numbers of immunizations, and time of chal-
lenge following immunization (Dean, 1983). Its proven efﬁcacy in
primates (Eberl et al., 2001; Kariuki et al., 2004) has reinforced
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the validity of the RA model, and it is still the gold standard
against which the protective efﬁcacies of recombinant antigens are
compared.
Although there is no doubt that the immune response elicited
by RA-vaccination mediates parasite attrition, there is no ﬁrm
consensus on the phenotype of the protective immune response.
Initial studies determined that reduction in challenge worm
burden in RA-immunized mice correlated with polarized Th1
immune responses, characterized by the production of interferon-
gamma (IFN-γ) by leukocytes in the airways of the lung (Smythies
et al., 1992; Wilson et al., 1996). However, signiﬁcant protection
in the RA model was also found in IL-12p40−/−mice (Anderson
et al., 1998, 1999), and nitric oxide was shown not to be a major
agent causing parasite elimination (Coulson et al., 1998). Further-
more, other studies have shown that effective immunity in the
RA vaccine model involved Th2 (Mountford et al., 2001) or mixed
Th1/Th2 (Hoffmann et al., 1999; Hewitson et al., 2005) immune
responses. In contrast, studies on humans that exhibit resistance to
infection following chemotherapy consistently indicate that Th2
immune responses correlate with protection (Ganley-Leal et al.,
2006; Walter et al., 2006; McManus and Loukas, 2008; Jiz et al.,
2009; Black et al., 2010a,b; Figueiredo et al., 2012; Fitzsimmons
et al., 2012; Pinot de Moira et al., 2013; Wilson et al., 2014). It is
possible that interpretation of these data is confounded by the
role of T-cells in schistosome development. While the complete
absence of CD4+ T-cells signiﬁcantly impairs parasite growth and
reproduction (Harrison and Doenhoff, 1983; Davies et al., 2001),
so too does the suppression of Th2 immune responses during
the pre-patent liver phase of infection (Riner et al., 2013). Both
the lung and liver represent the major sites of attrition in RA-
immunized mice challenged with S. mansoni (Laxer and Tuazon,
1992), suggesting that an alteration to the ﬁne balance of Th1
and Th2 immune responses that occur in these anatomical sites
at different times during natural infection may be sufﬁcient to
achieve protection, rather than a polarized response one way or
the other.
What is clear is that irradiated cercariae elicit the pro-
duction of IgG antibodies speciﬁc to parasite proteins, which
induce protection when passively transferred to mice (Abath
and Werkhauser, 1996). This correlates with the age-dependent
development of human immunological resistance to reinfection
with S. mansoni, which is also associated with the presence of
anti-tegument IgG antibodies (Karanja et al., 2002). In addi-
tion, it has been proposed that the resistance to re-infection
following chemotherapy with praziquantel, is mediated by anti-
bodies speciﬁc to schistosome antigens released upon worm
death that are not normally encountered by the host immune
response (Mutapi et al., 1998; Gomes et al., 2002). These obser-
vations prompted searches to identify those molecules recog-
nized by antibodies taken from RA cercariae-vaccinated mice,
or humans resistant to re-infection. The most prominent of
these were the tegument-associated antigens; Sm23 a member
of the tetraspanin family of surface molecules (Da’dara et al.,
2002, 2003), the fatty acid binding protein Sm14 (Tendler and
Simpson, 2008) and the apical lipid bilayer-associated glucose
transporter SGTP4 (Skelly et al., 1998; Krautz-Peterson et al.,
2010). Despite the induction of parasite-speciﬁc cytokines and
antibodies (Da’dara et al., 2002, 2003; Mahana, 2006), immu-
nization with these antigens failed to elicit protection above the
arbitrarily chosen 40% threshold (Bergquist and Colley, 1998).
Moreover, recent studies of human immune responses to these
candidates did not pin-point any with a particular potential
as a vaccine (Ribeiro de Jesus et al., 2000; Al-Sherbiny et al.,
2003).
It is likely that antigens on the surface membrane of schis-
tosome parasites are inaccessible to antibody binding (Keating
et al., 2006; Tallima and El Ridi, 2008) which ensures that the
antigens are protected behind a tight, almost impermeable,
sphingomyelin-based hydrogen-bond network (Tallima and El
Ridi, 2008; Migliardo et al., 2014). On the other hand, molecules
released by the parasite during migration and development
(termed excretory-secretory products; ESP) readily interact with
speciﬁc antibodies and other effectors of the host defense sys-
tem. Because the lung was demonstrated as the major site of
attrition of schistosomes after immunization with RA vaccines,
the early developing schistosome larvae are considered vulnerable
targets of innate and adaptive immunity (Dean, 1983; Coul-
son, 1997). We have suggested that effective immune responses
directed against these ESP harm the juvenile parasites as they
pass through the narrow and convoluted capillaries of the lung
(El Ridi et al., 2010). Therefore, the ESP represents a potential
pool of vaccine targets. A number of ESP of cercariae, in vitro-
cultured and ex vivo lung-stage schistosomula, and adult worms
of S. mansoni (Harrop et al., 1999; Knudsen et al., 2005; Cur-
wen et al., 2006; Hansell et al., 2008; El Ridi and Tallima, 2009),
S. japonicum (Liu et al., 2009; Liao et al., 2011) and S. haemato-
bium (Young et al., 2012) have been identiﬁed; molecules common
to these preparations include actin, heat shock proteins, enolase,
aldolase, glutathione S-transferase, triose phosphate isomerase,
glyceraldehyde 3-phosphate dehydrogenase (SG3PDH), 2 cis-
peroxyredoxin (PRX), and serine and, predominantly, cysteine
peptidases.
Schistosomes express several different classes of cysteine pep-
tidases. S. mansoni cathepsin B1 (SmCB1), a member of the
lysosomal cysteine peptidases of the papain superfamily,was found
to be expressed at high levels in the caecum and protonephridia
of cercariae. Expression increases in the parasite gut soon after
skin penetration and schistosomular transformation correspond-
ing to the initiation of blood feeding (Zerda et al., 1988). The
peptidase was reported to be the major hemoglobin-digesting
enzyme alongside another papain-like cysteine peptidase, cathep-
sin L1 (SmCL1), both of which are major proteins in worm soluble
extracts and ESP (Day et al., 1995; Dalton et al., 1996; Caffrey et al.,
1997; Brady et al., 1999a,b, 2000; Bogitsh et al., 2001). SmCL1 efﬁ-
ciently degrades human hemoglobin to absorbable dipeptides and
amino acids and is localized to the gastrodermis and to the tegu-
ment of adult worms. It displays 44% identity at the amino acid
level with a second cathepsin L (SmCL2) which, by contrast, is
not detected in cercarial extracts or gut caecum, but is predomi-
nantly localized to the reproductive system of the female parasite
and to the gynecophoric canal of the male, implying involve-
ment with the worm reproductive physiology (Dalton et al., 1996;
Brady et al., 1999a,b, 2000; Stack et al., 2011). More recently, a
third cathepsin L member, SmCL3, was shown to be expressed in
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the worm gastrodermis and was found to hydrolyze hemoglobin
and serum albumin (Dvorák et al., 2009). Furthermore, a second
cathepsin B (SmCB2) was localized to the schistosome tegu-
ment and may be involved in its biogenesis (Wippersteg et al.,
2005).
Cathepsin B and cathepsin L activities are readily detected by
enzymatic assays in S. mansoni cercarial extracts and may facili-
tate skin penetration (Dalton et al., 1997; Kasný et al., 2007, 2009;
Dvorák et al., 2008). 8–10day old cultured larvae of S.mansoni also
exhibited a dramatic increase in expression of these hemoglobin-
degrading peptidases (Zerda et al., 1988; Dalton et al., 1995; Dalton
and Brindley, 1996) and RNAi-mediated knockdown experiments
showed that at least for SmCB1 the parasites cannot feed in vitro
on hemoglobin and do not survive in vivo without this enzyme
(Correnti et al., 2005). More recently, using microarray analysis,
Gobert et al. (2010) showed that genes encoding cathepsin B and
cathepsin L were greatly up-regulated in S. mansoni larvae cul-
tured for 5 days (65 and 37-fold, respectively). Both SmCBs and
SmCLs are highly immunogenic in infected mice and antibodies
are detected in sera of S. mansoni-infected patients (Dalton et al.,
1995; Dalton and Brindley, 1996; Planchart et al., 2007; Sulbarán
et al., 2010).
The cathepsin B and L cysteine peptidases require the par-
asite gut-associated asparaginyl endopeptidase (Sm32) for their
activation from an inactive zymogen to fully active mature
enzyme (Dalton et al., 1995, 1996; Brindley et al., 1997; Skelly and
Shoemaker, 2001; Sajid et al., 2003; Delcroix et al., 2006; Krautz-
Peterson and Skelly, 2008; Stack et al., 2011). Sm32 is also a cysteine
peptidase, but is not a member of the papain superfamily (Dal-
ton et al., 1995; Dalton and Brindley, 1996). Given their central
importance in the biology of the parasite S. mansoni cysteine pep-
tidases have been of interest as both vaccine candidates for disease
prophylaxis and potential chemotherapeutic targets (Dalton and
Brindley, 1996; Wasilewski et al., 1996; Abdulla et al., 2007).
In addition to their role in the biology of the parasite, we
have shown that helminth cysteine peptidases have an ability to
modulate the host immune response (O’Neill et al., 2000; Don-
nelly et al., 2010). Cysteine peptidases from such diverse sources
as papaya (papain; Sokol et al., 2008), house dust mite (Derp1;
Roche et al., 1997; Kikuchi et al., 2006), Leishmania mexicana
(Pollock et al., 2003), and many fungal allergens (Shen et al.,
1998; Kheradmand et al., 2002) have all been shown to skew
the immune response toward a Th2 phenotype characterized by
the release of IL-33 and IL-4 and the production of antigen-
speciﬁc IgG1. Despite differences in amino acid sequence and
tertiary structure, their shared ability to induce Th2 immune
responses is dependent on their common enzymatic activity. Such
is the potency of their ability to modulate immune responses
that at low doses these cysteine peptidases can act as adjuvants,
inducing Th2 responses to bystander antigens in the absence
of another adjuvant (Chapman et al., 2007; Cunningham et al.,
2012). Indeed, we have shown that the subcutaneous adminis-
tration of papain prior to a challenge infection with S. mansoni,
switched the parasite-speciﬁc immune response toward a Th2
phenotype. Furthermore, this approach resulted in a signiﬁcant
level of protection (50%) from infection (El Ridi and Tallima,
2013).
The mechanism by which cysteine peptidase enzymes drive the
ampliﬁcation of Th2 immune responses is a subject of vigor-
ous research. It has been suggested that proteases may degrade
intracellular epithelia cell proteins, or damage epithelial cells,
for example in the lung, which respond by secreting stress-
related cytokines including IL-12, IL-33, and thymic stromal
lymphopoietin (TSLP), that subsequently activate mast cells and
basophils (Tang et al., 2010; Liang et al., 2012). Innate lympho-
cytes, termed lung natural helper (LNH) cells, which produce
IL-33 and TSLP, have also been implicated in papain-induced
airway inﬂammation (Halim et al., 2012). Recent studies have
indicated that a primary function of TSLP, produced as a result
of protease activity, is to prevent the induction of Th1-inducing
molecules such as IL-12 and CD70 from innate immune cells
(Massacand et al., 2009), which in turn facilitates the devel-
opment of Th2 immune responses. Interestingly, we found
that, like papain, a vaccine formulation containing a combina-
tion of TSLP or IL-33 and larval ESP molecules reproducibly
elicited production of parasite-speciﬁc Th2 cytokines and anti-
bodies in response to a challenge infection with S. mansoni.
Similar to the result achieved using papain, this vaccine formu-
lation also elicited a highly signiﬁcant (P < 0.0001) reduction
of 62 (TSLP) to 78% (IL-33) in worm burden and worm egg
load in host liver and small intestine (El Ridi and Tallima,
2013).
Indirectly, papain has been shown to mediate the differen-
tiation of macrophages toward a Th2-associated M2 phenotype
and via direct interaction, papain-treated macrophages are more
likely to differentiate into M2 cells after stimulation with bacterial
lipopolysaccharide, a ligand that more commonly induces inﬂam-
matory, Th1-associated M1 macrophages (Nhu et al., 2010, 2012).
Consistent with these observations, we have previously reported
that macrophages isolated from mice given a single parenteral
injection of either SmCB1 or a Fasciola hepatica cathepsin L1
(FhCL1) were inhibited in their ability to produce Th1-inducing
cytokines (Donnelly et al., 2010). The parasite proteases inhibited
the TLR-TRIF dependent mechanism of activation by Th1-
associated ligands and thus we proposed that these macrophages
were more permissive to stimulation with Th2-promoting ligands.
In the absence of TLR3-dependent signaling, production of Th2
cytokines is signiﬁcantly increased during a murine infection of
S. mansoni (Joshi et al., 2008).
Therefore, we suggested that, like papain, SmCB1 could act as
an adjuvant to elicit an antigen-speciﬁc Th2 immune response
to co-injected parasite molecules. However, we also proposed
that as immunization with SmCB1 would result in the produc-
tion of cathepsin B-speciﬁc antibodies, it would likely elicit a
higher level of protection than papain. To that end, SmCB1 was
administered subcutaneously to outbred mice, which were then
challenged with an infection of S. mansoni cercariae. Consis-
tent with the data seen for papain and in agreement with our
hypothesis, highly signiﬁcant (P < 0.0001) and reproducible
reduction of 50–70% in challenge worm burden was achieved
in ﬁve consecutive experiments. Protection was associated with
predominance of Th2-related cytokines and antibodies (El Ridi
et al., 2014). However, we found that the reduction in worm
egg counts in host liver and small intestine was not as striking
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as for the worm burden, in accordance with earlier ﬁndings
correlating Th2 dominant responses with increased schistosome
egg production (Wynn, 1999; Xu et al., 2009). Nevertheless,
we observed that when a mixture of SmCB1 and FhCL1 were
combined with the secreted proteins SG3PDH or SG3PDH and
PRX-MAP a highly signiﬁcant (P < 0.0001) and reproducible
reduction of 66% in challenge worm burden and in worm egg
load in liver and small intestine as well was achieved (El Ridi
et al., 2014). The data conﬁrmed that schistosome cysteine pep-
tidases have in-built immune modulating properties that are
protective on their own and have the potential to enhance the
protective responses to other molecules. In line with all the evi-
dence from allergen cysteine peptidases, this activity was related to
their enzymatic activity since SmCB1 inactivated with inhibitors
(E-64) or a non-active recombinant form of FhCL1 displayed
markedly reduced level of Th2 mediators, and was associated
with a signiﬁcant decrease in protective capacity (El Ridi et al.,
2014).
These results clearly demonstrate the induction of signiﬁ-
cant protection levels when an active parasite cysteine peptidase
enzyme is used in the vaccine formulation with no additional
requirement for an adjuvant. However, similar to the results
achieved with the RA vaccination model, we have found incon-
sistencies between the characteristics of the antigen-speciﬁc T-cell
response in protected animals. Instead, the key to the peptidase-
mediated protective effect may be the stimulation of a particular
type of antibody response. Mathematical models have concluded
that in younger, untreated endemic human populations, para-
site infections activate short-lived plasma cells that are essentially
non-protective. In contrast, in older populations the cumulative
deaths of infection worms, due to natural death or chemother-
apy, releases an antigen load which stimulates a different immune
response, characterized by the production of long-lived plasma
cells which reduces worm load (Mitchell et al., 2012). While it is
clear that cysteine proteases, irrespective of their source, clearly
induce the production of Th2-type antibodies against themselves
and bystander antigens, there has been no investigation into the
nature of antibody-producing B-cell. Recently, it was reported
that immunization of mice with low doses of a ﬁsh venom
protease (Natterin), induced the differentiation of terminally dif-
ferentiated, long-lived antibody-secreting cells and that this was
dependent on the proteolytic activity of the natterin (Komegae
et al., 2013). In addition, these authors demonstrated that the
production of both IL-5 and IL-17 in response to the venom pro-
tease directly inﬂuenced themaintenance of the antibody secreting
cells in the spleen (Grund et al., 2012). Therefore, its seems that
the enzymatic activity of cysteine proteases, besides inducing
antigen-speciﬁc cytokines, is also essential to generate survival
signals necessary for the longevity of antibody secreting plasma
cells.
Such potent, adjuvant-like effects of the cysteine peptidases
may offer an innovative and feasible approach to developing a
human vaccine formulation for protection against schistosomi-
asis. As we have learned, the delivery of parasite-secreted active
cysteine peptidases alone or combined with other schistosome
vaccine candidates, elicited levels of protection comparable to the
bench-mark treatment of RA-cercariae. To date, the failure of
many anti-schistosome vaccines has been attributed to the use
of inappropriate adjuvants and/or delivery systems. Our data
indicates that inclusion of active cysteine peptidases with in-
built immunopotentiating activity in a vaccine preparation could
preclude the need for a chemical adjuvant.
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